NCT01803438 - Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 16, 2019

Study Completion Date

January 20, 2020

Conditions

Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases

Interventions

DEVICE

cryoballoon ablation system

DRUG

Antiarrhythmic Drugs

AAD therapy based on hospital clinical practice according to ESC Guidelines 2012

Trial Locations (19)

20246

Universitätsklinikum Eppendorf, Hamburg

48033

Maria Cecilia Hospital, Cotignola

60431

Cardioangiologisches Centrum Bethanien, Frankfurt

67655

Westpfalz-Klinikum GmbH, Kaiserslautern

C1428

nstituto Cardiovascular de Buenos Aires, Buenos Aires

Unknown

Monash Medical Centre, Melbourne

Heart Rhythm Management Centre, UZ Brussels - VUB Brussel, Brussels

Klinicki bolnicki centar Sestre Milosrdnice, Zagreb

Klinicki bolnicki centar Sestre, Zagreb

NCHU Amiens, Amiens

CHU Grenoble, Grenoble

CHU La Pitié, Paris

CHU Charles Nicolle, Rouen

Kerckhoff - Klinik, Bad Nauheim

Klinikum Bogenhausen, Munich

Ospedale S.S. Giacomo e Cristoforo, Massa

Erasmus MC, Rotterdam

Haukeland Hospital, Bergen

5623 EJ

Catharina Ziekenhuis, Eindhoven

All Listed Sponsors

lead

Medtronic Cardiac Ablation Solutions

INDUSTRY